Demonstration of the Need for Cardiovascular and Pulmonary Normative Data for Cancer Survivors

Abstract

Despite evidence that cancer and its treatments severely reduce cardiorespiratory fitness (CRF), normative data for cancer survivors do not exist. The present study identifies age and gender-specific CRF distributions in a cancer population. The use of cancer-specific normative CRF data may help stratify initial fitness status and assess improvements in response to exercise interventions in cancer survivors. Data from 703 cancer survivors were analyzed for this study. Quintiles were compiled for peak oxygen consumption (VO₂peak), forced vital capacity (FVC), and forced expiratory volume (FEV₁) for males and females in 5 age groups (19–39, 40–49, 50–59, 60–69, and ≥70 years of age). VO₂peak values for the cancer population were significantly lower than the general US population. The cancer population average in each age group fell within the “very poor” classification of VO₂peak values for the general population. FVC values in the cancer population were similar to the general population. Cancer survivors had very low age group-specific VO₂peak values compared to the apparently healthy general US population. Previously, CRF values of cancer survivors were compared to normative values for the apparently healthy general population, which yielded imprecise classifications of initial fitness and changes in fitness, resulting in patient discouragement.

Key words

cancer rehabilitation - population-specific ­normative values - exercise - cancer treatment side ­effects

• References

• 1 Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ. ASCO Cancer Survivorship Expert Panel . American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007; 25: 3991-4008
• 2 Centers for Disease Control and Prevention . Adult participation in aerobic and muscle-strengthening physical activities – United States, 2011. MMWR Morb Mortal Wkly Rep 2013; 62: 326-330
• 3 Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, Kalyanaraman B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J 2009; 96: 1388-1398
• 4 Cunningham AJ, Lockwood GA, Cunningham JA. A relationship between perceived self-efficacy and quality of life in cancer patients. Patient Ednc Couns 1991; 17: 71-78
• 5 DeVita V, Hellman S, Rosenberg S. (ed. Cancer: Principles and Practice of Oncology. 7^th ed. Philadephia: Lippincott Williams & Wilkins; 2005
• 6 Dimeo F, Fetscher S, Lange W, Mertelsmann R, Keul J. Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood 1997; 90: 3390-3394
• 7 Ewer MS, Swain SM, Cardinale D, Fadol A, Suter TM. Cardiac dysfunction after cancer treatment. Texas Heart Inst J 2011; 38: 248-252
• 8 Harriss DJ, Atkinson G. Ethical standards in sports and exercise science research: 2014 update. Int J Sports Med 2013; 34: 1025-1028
• 9 Hayward R, Hydock DS. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci 2007; 46: 20-32
• 10 Hydock DS, Lien CY, Hayward R. Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. J Cardiovasc Pharmacol Ther 2009; 14: 59-67
• 11 Jones LW, Eves ND, Mackey JR, Peddle CJ, Haykowsky M, Joy AA, Courneya KS, Tankel K, Spratlin J, Reiman T. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung cancer 2007; 55: 225-232
• 12 Lind PA, Rosfors S, Wennberg B, Glas U, Bevergård S, Fornander T. Pulmonary function following adjuvant chemotherapy and radiotherapy for breast cancer and the issue of three-dimensional treatment planning. Radiother Oncol 1998; 49: 245-254
• 13 Makker V, Spriggs D. Principles of Chemotherapy. In: Stubblefield MD, O'Dell MW. eds. Cancer Rehabilitation: Principles and Practice. New York: Demos Medical Publishing; 2009: 23-52
• 14 Schneider CM, Dennehy CA, Carter SD. Exercise and Cancer Recovery. Champaign: Human Kinetics; 2003
• 15 Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R. Cancer treatment-induced alterations in muscular fitness and quality of life: the role of exercise training. Ann Oncol 2007; 18: 1957-1962
• 16 Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep: PR 2009; 61: 154-171
• 17 Smets EM, Garssen B, Schuster-Uitterhoeve AL, de Haes JC. Fatigue in cancer patients. Br J Cancer 1993; 68: 220-224
• 18 Starkweather A. Increased interleukin-6 activity associated with painful chemotherapy-induced peripheral neuropathy in women after breast cancer treatment. Nurs Res Pract 2010; 2010: 281531
• 19 Theuws JC, Muller SH, Seppenwoolde Y, Kwa SL, Boersma LJ, Hart GA, Baas P, Lebesque JV. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study. J Clin Oncol 1999; 17: 3091-3100
• 20 Thomson WR, Gordon NF, Pescatello L. ACSM’s Guidelines for Exericse Testing and Prescription. 8^th ed Baltimore, MD: Lippincott Williams & Wilkins; 2010
• 21 Thorsen L, Nystad W, Stigum H, Hjermstad M, Oldervoll L, Martinsen EW, Hornslien K, Strømme SB, Dahl AA, Fosså SD. Cardiorespiratory fitness in relation to self-reported physical function in cancer patients after chemotherapy. The J Sports Med Phys Fitness 2006; 46: 122-127
• 22 Wampler MA, Topp KS, Miaskowski C, Byl NN, Rugo HS, Hamel K. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil 2007; 88: 1002-1008
• 23 Wauters I, Vansteenkiste J. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy. Expert Rev Anticancer Ther 2012; 12: 1383-1390